Aclaris therapeutics provides r&d update

Wayne, pa., jan. 11, 2022 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (r&d) operations.
ACRS Ratings Summary
ACRS Quant Ranking